Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 20.09.2026 | Accepted 21.09.2026 | Online 25.09.2026

BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF CHRONIC PSYCHOTROPIC DRUG ADMINISTRATION

Sophie L. Harrington
Department of Neuropharmacology and Behavioral Sciences
London Biomedical Research Institute, United Kingdom
sophie.harrington@lbri-ac.uk

Abstract

Chronic administration of psychotropic drugs produces therapeutic effects that often emerge together with time-dependent neurochemical and behavioral adaptations. These adaptations extend beyond acute receptor occupancy and include altered receptor density and coupling, neurotransmitter synthesis and release, intracellular signaling, gene transcription, neurotrophin regulation, synaptic remodeling, and circuit-level plasticity. The present evidence-based structured review synthesizes preclinical and clinical findings on long-term exposure to antidepressants, antipsychotics, benzodiazepines, lithium, and valproate. Particular attention is given to serotonin and norepinephrine adaptation, BDNF-TrkB and CREB signaling, dopamine D2 receptor regulation, GABA-A receptor plasticity, glutamatergic counter-regulation, GSK3-dependent pathways, histone deacetylase modulation, and the relationship of these changes to efficacy, tolerance, dependence, emotional blunting, tardive phenomena, cognition, and relapse vulnerability. The evidence indicates that chronic psychotropic treatment should be understood as a dynamic interaction between therapeutic neuroplasticity and homeostatic compensation. Antidepressants are associated with delayed neurotrophic and synaptic adaptations; chronic D2 antagonism can provoke striatal dopaminergic compensation in susceptible contexts; prolonged benzodiazepine exposure induces inhibitory synaptic remodeling that contributes to tolerance and withdrawal; and mood stabilizers exert broader intracellular and neuroprotective actions. Translation from animal models to humans remains incomplete, and many long-term effects are strongly influenced by dose, duration, diagnosis, age, co-medication, and withdrawal conditions. Rational psychopharmacology therefore requires periodic reassessment, gradual dose changes when clinically appropriate, and monitoring for class-specific neurobehavioral consequences.

Keywords: psychotropic drugs; chronic administration; neuroadaptation; antidepressants; antipsychotics; benzodiazepines; lithium; valproate; neuroplasticity; BDNF; dopamine; GABA.

1. Introduction

Psychotropic medicines are commonly evaluated through their acute pharmacodynamic actions, yet most clinical treatment courses extend for weeks, months, or years. During this period the brain does not remain pharmacologically static. Continuous

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

or repeated receptor engagement triggers compensatory processes at molecular, cellular, synaptic, and network levels. These processes can contribute to therapeutic delay, maintenance of response, tolerance, adverse effects, withdrawal phenomena, and changes in relapse risk. The distinction between the immediate drug effect and the chronic adaptive response is therefore central to modern neuropsychopharmacology (1,4,7).

For antidepressants, inhibition of monoamine reuptake occurs rapidly, whereas clinically meaningful improvement usually develops more slowly. This temporal dissociation encouraged investigation of downstream plasticity, including cAMP-response element-binding protein (CREB), brain-derived neurotrophic factor (BDNF), TrkB signaling, dendritic remodeling, and hippocampal neurogenesis (1,2). In contrast, antipsychotic drugs often produce substantial D2 receptor occupancy within hours, but sustained treatment can induce compensatory changes in dopaminergic signaling, receptor density, and striatal responsiveness. Human evidence for clinically important dopamine supersensitivity is less complete than the preclinical literature, but D2 up-regulation has been documented and remains a relevant mechanistic concern during long-term exposure and medication changes (4–6).

Long-term benzodiazepine use offers another example of pharmacological adaptation. Positive allosteric modulation of GABA-A receptors initially increases inhibitory tone, but repeated exposure can alter receptor subunit expression, receptor trafficking, synaptic coupling, and excitatory-inhibitory balance. These adaptations help explain why tolerance develops to some benzodiazepine effects and why abrupt discontinuation may reveal a hyperexcitable state (7,8). Mood stabilizers operate through still broader intracellular mechanisms. Lithium influences GSK3, inositol signaling, neurotrophic pathways, mitochondrial function, and oxidative stress, whereas valproate alters GABAergic transmission, voltage-dependent ion channels, and histone deacetylase activity (9,10).

The aim of this review is to integrate behavioral and neurochemical consequences of chronic psychotropic drug administration across major therapeutic classes. The focus is not to label adaptation as intrinsically beneficial or harmful, but to distinguish adaptive mechanisms that may support sustained therapeutic efficacy from those associated with tolerance, dependence, functional impairment, or treatment complications.

2. Materials and Methods

A structured narrative review was performed using peer-reviewed literature indexed in PubMed and major biomedical journal platforms, emphasizing mechanistic reviews, translational studies, clinical imaging studies, and recent syntheses available through September 2026. Search concepts included chronic psychotropic administration, antidepressant neuroplasticity, BDNF, emotional blunting, antipsychotic neuroadaptation, dopamine D2 up-regulation, dopamine supersensitivity, benzodiazepine tolerance, GABA-A receptor plasticity, lithium neuroprotection, GSK3, valproate HDAC inhibition, cognition, and withdrawal. Older landmark studies were retained when they defined mechanisms still used in current models, while recent 2023–2026 sources were prioritized for updated interpretation (1–15).

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

Evidence was organized by drug class and by level of adaptation: receptor and transporter regulation; neurotransmitter release and turnover; intracellular signaling and transcription; neurotrophic and synaptic plasticity; circuit-level consequences; and observable behavioral outcomes. Because the source literature includes heterogeneous animal models, observational human studies, imaging research, and clinical reviews, no pooled effect estimate was calculated. Mechanistic statements were classified qualitatively and interpreted with attention to translational limitations, treatment duration, exposure pattern, and withdrawal conditions.

Table 1. Major chronic adaptations associated with psychotropic drug classes

Drug class	Primary acute target	Representative chronic adaptation	Behavioral/clinical correlate
Antidepressants	5-HT/NE transporters; receptor modulation	CREB-BDNF/TrkB signaling, synaptic remodeling, receptor desensitization	Delayed therapeutic response, improved stress resilience; possible emotional blunting in a subset
Antipsychotics	Dopamine D2 receptor antagonism/partial agonism; 5-HT effects	Changes in D2 density/affinity, dopamine output, downstream signaling	Maintenance efficacy, extrapyramidal effects, tardive phenomena; possible supersensitivity in susceptible cases
Benzodiazepines	Positive allosteric modulation of GABA-A receptors	Subunit expression, receptor coupling/trafficking, glutamatergic counter-regulation	Tolerance to sedative/anticonvulsant effects, dependence, withdrawal hyperexcitability
Lithium	Intracellular enzymes and second messengers	GSK3 inhibition, neurotrophic signaling, mitochondrial and anti-apoptotic effects	Mood stabilization, potential neuroprotection; narrow therapeutic index requires monitoring
Valproate	GABA, Na+/Ca2+ channels, HDAC inhibition	Transcriptional/epigenetic modulation and inhibitory signaling changes	Mood stabilization and anticonvulsant effects; cognitive and systemic adverse effects in some patients

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

3. Results

3.1 Antidepressants: monoamine adaptation and neuroplasticity

Chronic antidepressant exposure demonstrates the difference between acute target engagement and delayed systems-level response. Selective serotonin reuptake inhibitors (SSRIs) rapidly increase extracellular serotonin, and serotonin-norepinephrine reuptake inhibitors increase one or both monoamines. Repeated exposure, however, changes the responsiveness of autoreceptors and postsynaptic receptors, intracellular cAMP signaling, CREB activity, neurotrophin expression, and synaptic structure. Classical work linked chronic antidepressant treatment with increased hippocampal neurogenesis and enhanced CREB-BDNF signaling, providing a biological framework for delayed clinical improvement (1). More recent reviews continue to support an association between antidepressant treatment, BDNF-related signaling, and neuroplasticity while emphasizing substantial methodological heterogeneity in peripheral BDNF measurement and uncertainty about direct correspondence between blood and brain concentrations (2,11).

BDNF is particularly relevant because it regulates dendritic growth, synapse formation, neuronal survival, and activity-dependent plasticity. Repeated antidepressant treatment may increase the capacity of neural circuits to reorganize rather than producing a simple fixed increase in monoamine transmission. This "plasticity-enabling" view also helps explain why pharmacological treatment may interact with environmental context, psychotherapy, learning, and stress exposure. Nevertheless, evidence from rodents cannot be mapped directly onto every human antidepressant response, and different drug classes do not produce identical molecular signatures (1,2).

Behavioral effects of long-term antidepressant use include symptom remission and reduced recurrence in responsive patients, but some individuals report emotional blunting, apathy-like experiences, reduced reward sensitivity, or sexual dysfunction. A 2023 scoping review concluded that emotional blunting can be associated with antidepressant exposure in at least a subset of patients, while also recognizing that residual depressive symptoms can produce a similar phenotype and that causal attribution is difficult (3). Neurobiologically, hypotheses include excessive serotonergic dampening of reward processing, altered dopaminergic salience, and adaptive changes in frontolimbic networks, but these mechanisms remain incompletely established.

Table 2. Chronic antidepressant effects and interpretive considerations

Domain	Long-term change described in literature	Potential consequence	Evidence caveat
Serotonergic signaling	Autoreceptor/postsynaptic receptor adaptation and altered network gain	Reduced anxiety/depressive symptoms after delayed adaptation	Magnitude varies by drug, dose, and brain region

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

Domain	Long-term change described in literature	Potential consequence	Evidence caveat
Neurotrophic pathways	CREB-BDNF/TrkB signaling and plasticity-related gene expression	Synaptic remodeling, stress resilience, possible neurogenesis	Human peripheral BDNF is an imperfect proxy for CNS signaling
Reward/affect	Possible reduction in affective intensity in a subset of SSRI-treated patients	Emotional blunting or apathy-like complaints	Can overlap with residual depression
Withdrawal/rebound	Neuroadaptation to sustained transporter blockade	Discontinuation symptoms after rapid cessation in some patients	Risk is influenced by half-life, duration, and tapering strategy

Figure 1. Conceptual cascade of neuroadaptation during chronic psychotropic drug administration




Figure 1. Conceptual cascade of neuroadaptation during chronic psychotropic drug administration.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

3.2 Antipsychotics: dopaminergic compensation and circuit-level adaptation

Most antipsychotic drugs reduce dopamine D2-mediated signaling, directly through antagonism or functionally through partial agonist mechanisms. Chronic exposure can produce changes that are not predicted from acute receptor occupancy alone. Preclinical and post-mortem research describes adaptations in dopamine receptors, monoamine release, transporter expression, intracellular signaling, and brain metabolic systems (4). Dopamine D2 receptor up-regulation after sustained blockade is a recurring experimental finding and has also been observed in human imaging studies, although the magnitude and clinical meaning vary (6,12).

The concept of antipsychotic-evoked dopamine supersensitivity proposes that sustained D2 blockade can produce a state of increased dopaminergic responsiveness, potentially contributing to loss of efficacy, rebound psychosis after abrupt dose reduction, or tardive motor phenomena in susceptible patients. Contemporary reviews emphasize that evidence is strongest in animal models; in humans, illness course, adherence, stress, pharmacokinetics, and treatment history are major confounders (5,6). Therefore, dopamine supersensitivity should be viewed as a plausible mechanistic contributor rather than a universal consequence of maintenance antipsychotic treatment.

Chronic antipsychotic administration can also alter glutamatergic, GABAergic, cholinergic, serotonergic, metabolic, mitochondrial, and inflammatory pathways. The 2026 literature on tardive dyskinesia increasingly frames delayed motor toxicity as a disorder of pathological neuroplasticity involving multiple systems rather than D2 receptor up-regulation alone (13). Clinically, long-term treatment may be associated with extrapyramidal symptoms, tardive dyskinesia, hyperprolactinemia, sedation, cognitive slowing in some individuals, and metabolic complications that indirectly influence brain health. At the same time, sustained antipsychotic treatment is strongly beneficial for many patients at high risk of psychotic relapse; mechanistic concerns about adaptation should not be interpreted as evidence for abrupt discontinuation.

Table 3. Neurobehavioral effects of chronic antipsychotic and benzodiazepine exposure

Class	Neurochemical adaptation	Behavioral/clinical expression	Key interpretation
Antipsychotics	D2 receptor regulation; altered dopamine release and downstream signaling	Maintenance efficacy; possible tolerance-like loss of effect, rebound vulnerability, tardive dyskinesia	Human causality is difficult to separate from illness progression and exposure history
Antipsychotics	Serotonergic, glutamatergic, GABAergic and metabolic adaptations	Changes in cognition, motivation, motor control and metabolic state	Drug-specific receptor profiles produce different long-term signatures

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

Class	Neurochemical adaptation	Behavioral/clinical expression	Key interpretation
Benzodiazepines	GABA-A receptor subunit/coupling and trafficking changes	Reduced sedative effect, dependence, cognitive/psychomotor impairment	Tolerance develops unevenly across pharmacological effects
Benzodiazepines	Excitatory counter-regulation and synaptic remodeling	Withdrawal anxiety, insomnia, tremor or seizures after abrupt cessation in dependent states	Withdrawal risk reflects dose, duration, half-life and rate of dose reduction

3.3 Benzodiazepines: inhibitory synaptic remodeling, tolerance and dependence

Benzodiazepines enhance the action of GABA at benzodiazepine-sensitive GABA-A receptors. With repeated exposure, the inhibitory system adapts. Mechanisms described in experimental literature include altered receptor subunit expression, changes in receptor phosphorylation and intracellular trafficking, reduced functional coupling between the benzodiazepine recognition site and GABA-mediated channel opening, and compensatory changes in glutamatergic transmission (8). These adaptations do not develop uniformly across behavioral effects. Tolerance tends to emerge more clearly for sedation and anticonvulsant activity than for every anxiolytic response (8).

A 2026 review of synaptic correlates emphasizes that prolonged benzodiazepine exposure can reorganize inhibitory and excitatory synapses and may produce long-lasting changes in stress, arousal, and reward circuitry (7). Dependence and tolerance are related but not identical: physiological dependence can occur without marked tolerance to a particular therapeutic effect, and tolerance can occur without the full clinical syndrome of dependence. When a dependent nervous system is exposed to abrupt dose reduction, compensatory excitatory mechanisms may become unmasked and generate withdrawal symptoms. This is a clinically important example of a chronic neurochemical adaptation becoming behaviorally evident only after drug removal.

Long-term benzodiazepine exposure has also been associated with impaired attention, psychomotor performance, and memory in some populations. Interpretation is complicated by confounding from anxiety, insomnia, age, co-prescribed sedatives, and indication severity. Nevertheless, chronic exposure—particularly in older adults or in combination with other central nervous system depressants—requires periodic reassessment of benefit, sedation, falls, cognition, and dependence risk (7,8).

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

3.4 Mood stabilizers: lithium, valproate and intracellular adaptation

Lithium differs from receptor-selective psychotropics because its long-term effects arise from distributed intracellular actions. Proposed mechanisms include inhibition of glycogen synthase kinase-3 (GSK3), modulation of inositol signaling and protein kinase pathways, increased expression of neurotrophic and anti-apoptotic factors, improved mitochondrial function, and reduction of oxidative stress (9,14). Neuroimaging and translational studies have associated lithium exposure with structural and neurotrophic effects in the hippocampus and other regions, although these findings do not imply that every patient will demonstrate measurable cognitive or structural benefit. A 2026 systematic review of randomized evidence found no consistent global cognitive improvement or worsening across bipolar disorder trials, reinforcing the need for cautious interpretation of neuroprotection claims (15).

Valproate increases inhibitory GABAergic tone, modulates sodium and calcium channels, and inhibits histone deacetylases (HDACs), giving it a distinctive epigenetic dimension. Long-term HDAC inhibition can alter transcriptional programs relevant to neuronal plasticity and development. Current reviews emphasize the dual nature of valproate: neuroprotective effects are observed in some experimental contexts, but chronic clinical use can also be associated with sedation, tremor, weight gain, cognitive complaints, hepatotoxicity, thrombocytopenia, and major teratogenic risk (10). Thus, chronic biochemical modulation should be interpreted alongside systemic safety rather than as a purely central nervous system phenomenon.


Table 4. Long-term mood-stabilizer mechanisms and clinical monitoring domains

Agent	Long-term molecular actions	Potential behavioral relevance	Monitoring implications
Lithium	GSK3 inhibition; inositol/PKC signaling; BDNF and anti-apoptotic pathways; mitochondrial effects	Mood stabilization, reduced recurrence; possible neuroprotective actions	Serum concentration, renal and thyroid function, fluid balance, drug interactions
Valproate	GABA enhancement; Na+/Ca2+ channel modulation; HDAC inhibition and transcriptional effects	Antimanic/anticonvulsant effects; sedation or cognitive complaints in some patients	Liver function, blood count, weight/metabolic status; strict reproductive safety considerations
Class principle	Slow systems-level adaptation rather than single-receptor action	Therapeutic effects may persist through network stabilization	Periodic reassessment of benefit, adverse effects and

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

Agent	Long-term molecular actions	Potential behavioral relevance	Monitoring implications
			necessity of maintenance treatment

Figure 2. Dominant long-term neurochemical adaptations by psychotropic drug class



The figure is qualitative and summarizes mechanisms supported to different degrees by preclinical and clinical evidence.

Figure 2. Dominant long-term neurochemical adaptations by psychotropic drug class (qualitative synthesis).

3.5 Cross-cutting mechanisms: homeostasis, metaplasticity and treatment duration

Despite major pharmacological differences, several cross-cutting principles are evident. First, chronic drug exposure activates homeostatic mechanisms that oppose or reshape the initial pharmacological perturbation. Receptor up- or down-regulation, altered second-messenger signaling, transporter changes, and synaptic scaling are examples. Second, long-term treatment may change the capacity of neural circuits to undergo subsequent plasticity—a concept sometimes described as metaplasticity. This can be therapeutically useful when treatment restores adaptive learning, but it may also contribute to dependence, rebound, or delayed adverse effects when the system becomes optimized around continued drug exposure.

Third, the pattern of exposure matters. Continuous high receptor occupancy may produce different adaptations from intermittent or low-level exposure. Drug half-life, active metabolites, dose timing, age, hepatic or renal impairment, genetic variation, and interacting medicines change the effective neurochemical “training signal” delivered to the

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

nervous system. Fourth, withdrawal is itself an experimental perturbation: observations made after abrupt drug cessation may reflect both the underlying illness and a transient counter-regulatory state. This is particularly important when interpreting recurrence after benzodiazepines, antidepressants, or antipsychotics (3,5–8).

Finally, behavioral outcomes cannot be inferred from a single molecular marker. Increased BDNF, D2 receptor density, GABA-A subunit changes, or GSK3 inhibition are mechanistically informative but do not uniquely determine mood, cognition, relapse, or functional outcome. Psychiatric behavior emerges from distributed networks and is influenced by psychological, social, sleep-related, endocrine, and metabolic factors. For this reason, mechanistic monitoring should complement rather than replace careful clinical assessment.

3.6 Behavioral endpoints and translational interpretation

Behavioral pharmacology translates molecular adaptation into observable function, but the meaning of a behavioral endpoint depends on species, test design, baseline disease state, and timing relative to drug administration. Chronic antidepressant studies commonly examine stress-coping, reward preference, social interaction, sleep-related behavior, and cognitive flexibility, whereas chronic antipsychotic studies often assess locomotor response, conditioned avoidance, sensorimotor gating, stereotypy, and motor side effects. Benzodiazepine studies focus on sedation, anxiolysis, anticonvulsant effects, motor coordination, memory, and withdrawal-related hyperexcitability. These outcomes are useful for detecting adaptation, but no single animal test is equivalent to a psychiatric symptom in humans.

A central translational problem is that behavioral improvement and neurochemical normalization do not always move in parallel. For example, receptor adaptation may be measurable before a change in clinical symptoms, while a stable clinical response may persist despite ongoing molecular compensation. Conversely, withdrawal-related behavior may emerge rapidly even when the underlying receptor changes developed slowly over weeks. Interpretation therefore requires temporal mapping: baseline state, early exposure, established maintenance, dose reduction, and post-discontinuation phases should be analyzed separately.

The most informative long-term studies combine multiple levels of measurement: behavior, receptor occupancy, neurotransmitter release, electrophysiology, structural imaging, molecular markers, and functional outcomes. In clinical practice, an analogous multidimensional approach includes symptom severity, quality of life, cognition, sleep, motor examination, metabolic health, patient-reported adverse effects, adherence, and functioning. This reduces the risk of treating a biomarker as a surrogate for the whole patient and supports individualized interpretation of chronic psychotropic adaptation.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

Table 5. Behavioral domains commonly used to evaluate chronic psychotropic effects

Behavioral domain	Typical measures	Drug classes commonly studied	Interpretive caution
Affect/stress coping	Stress-coping tasks, reward preference, social interaction	Antidepressants, mood stabilizers	Animal behavior models dimensions of illness, not full clinical syndromes
Motor/dopamine responsiveness	Locomotor activity, stereotypy, conditioned avoidance, motor scales	Antipsychotics	Motor activation can reflect both therapeutic and adverse dopaminergic adaptation
Sedation/anxiety	Exploration, motor coordination, anxiety-related paradigms	Benzodiazepines, antidepressants	Sedation can confound apparent anxiolytic effects
Cognition	Memory, attention, reversal learning, executive tasks	All major classes	Performance is influenced by sedation, motivation, illness and practice effects
Withdrawal/rebound	Autonomic signs, sleep disruption, anxiety, hyperexcitability	Benzodiazepines, antidepressants, antipsychotics	Timing and taper rate strongly influence observed behavior

4. Discussion

The reviewed evidence supports a unified interpretation of chronic psychopharmacology: sustained drug administration is a process of repeated biological perturbation followed by adaptive re-equilibration. Therapeutic benefit often depends on this re-equilibration. Antidepressants illustrate this clearly, because transporter blockade is immediate while neurotrophic and network-level changes evolve more slowly. Lithium and valproate likewise exert effects that extend well beyond acute synaptic transmission into gene regulation, cellular resilience, and intracellular signaling (1,2,9,10).

At the same time, homeostatic adaptation can create clinical liabilities. D2 receptor up-regulation and associated dopaminergic sensitization are biologically plausible consequences of chronic D2 blockade, but the prevalence and clinical impact in humans remain uncertain and should not be overstated (5,6). Benzodiazepine tolerance and

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 20.09.2026 Accepted 21.09.2026 Online 25.09.2026

dependence have stronger convergent support, with receptor-level and synaptic mechanisms now increasingly integrated into circuit models (7,8). Emotional blunting during antidepressant treatment remains a clinically recognized but mechanistically unresolved phenomenon, complicated by overlap with residual depression and by substantial variability among patients (3).

These findings have practical implications. Chronic psychotropic treatment should be reviewed longitudinally rather than assumed to have a fixed benefit-risk profile. Monitoring should include target symptoms, functioning, cognition, sleep, motor symptoms, metabolic parameters, endocrine effects where relevant, and signs of tolerance or withdrawal. Dose changes should consider the pharmacokinetic and neuroadaptive properties of the drug. Abrupt discontinuation of a chronically administered psychotropic agent can transform a stable adapted state into an unstable one, and therefore treatment changes often require gradual, clinically supervised strategies tailored to the specific drug and patient.

The evidence base also has important limitations. A large proportion of mechanistic data arises from animal studies using exposure schedules that do not fully reproduce human treatment. Clinical imaging can identify receptor or structural changes but cannot easily establish whether these changes are caused by the medication, the disorder, prior treatment, or selection effects. Peripheral biomarkers such as BDNF are convenient but are imperfect proxies for central synaptic biology. Long-term randomized trials are difficult for ethical and practical reasons, so observational evidence remains important but vulnerable to confounding. These limitations argue for careful language: chronic psychotropic exposure clearly produces neuroadaptation, but the direction, magnitude, reversibility, and clinical meaning of each adaptation are not uniform.

Future studies should combine longitudinal receptor imaging, digital behavioral phenotyping, pharmacogenomics, multimodal electrophysiology, metabolomics, and patient-reported outcomes. Such approaches may identify subgroups in whom a particular adaptation predicts sustained response, adverse effects, or withdrawal vulnerability. A precision-psychopharmacology framework would shift the focus from drug class averages toward individualized trajectories of neurochemical adaptation.

5. Conclusion

Chronic psychotropic drug administration produces complex behavioral and neurochemical effects that differ fundamentally from acute pharmacological actions. Antidepressants engage delayed neurotrophic and synaptic plasticity mechanisms; antipsychotics can induce compensatory dopaminergic and multi-transmitter adaptations; benzodiazepines remodel inhibitory synapses and can generate tolerance and dependence; and lithium and valproate alter broad intracellular, neurotrophic, and epigenetic pathways. These processes may sustain treatment efficacy, but they can also contribute to emotional blunting, cognitive effects, motor complications, tolerance, withdrawal, or rebound in susceptible individuals. The strongest clinical approach is therefore dynamic: treatment indication, dose, duration, adverse effects, and functional outcomes should be reassessed

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 20.09.2026 | Accepted 21.09.2026 | Online 25.09.2026

over time, and medication changes should account for the adapted state of the nervous system.

References

1. D'Sa, C., & Duman, R. S. (2002). Antidepressants and neuroplasticity. Bipolar Disorders, 4(3), 183–194. https://doi.org/10.1034/j.1399-5618.2002.01203.x
2. Esalatmanesh, S., Kashani, L., & Akhondzadeh, S. (2023). Effects of antidepressant medication on brain-derived neurotrophic factor concentration and neuroplasticity in depression: A review of preclinical and clinical studies. Avicenna Journal of Medical Biotechnology, 15(3), 129–138. https://doi.org/10.18502/ajmb.v15i3.12921
3. Jawad, M. Y., Fatima, M., Hassan, U., Zaheer, Z., Ayyan, M., Ehsan, M., et al. (2023). Can antidepressant use be associated with emotional blunting in a subset of patients with depression? A scoping review of available literature. Human Psychopharmacology: Clinical and Experimental, 38(4), e2871. https://doi.org/10.1002/hup.2871
4. Amato, D., Beasley, C. L., Hahn, M. K., & Vernon, A. C. (2017). Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. Neuroscience & Biobehavioral Reviews, 76(Pt B), 317–335. https://doi.org/10.1016/j.neubiorev.2016.10.004
5. Servonnet, A., & Samaha, A.-N. (2020). Antipsychotic-evoked dopamine supersensitivity. Neuropharmacology, 163, 107630. https://doi.org/10.1016/j.neuropharm.2019.05.007
6. Thompson, I. A., de Vries, E. F. J., & Sommer, I. E. C. (2020). Dopamine D2 up-regulation in psychosis patients after antipsychotic drug treatment. Current Opinion in Psychiatry, 33(3), 200–205. https://doi.org/10.1097/YCO.0000000000000598
7. Piot, A., & Jovanovic, J. N. (2026). Synaptic correlates of benzodiazepine tolerance. Molecular Psychiatry, 31, 3775–3785. https://doi.org/10.1038/s41380-026-03512-8
8. Vinkers, C. H., & Olivier, B. (2012). Mechanisms underlying tolerance after long-term benzodiazepine use: A future for subtype-selective GABAA receptor modulators? Advances in Pharmacological Sciences, 2012, 416864. https://doi.org/10.1155/2012/416864
9. Ochoa, E. L. M. (2022). Lithium as a neuroprotective agent for bipolar disorder: An overview. Cellular and Molecular Neurobiology, 42(1), 85–97. https://doi.org/10.1007/s10571-021-01129-9
10. Abd-Eldayem, A. M. (2026). Valproic acid: Mechanistic insights into neuronal actions, epigenetic modulation, and clinical risk. Current Opinion in Pharmacology, 88, 102626. https://doi.org/10.1016/j.coph.2026.102626
11. The effect of antidepressant treatment on blood BDNF levels in depressed patients: A review and methodological recommendations for assessment of BDNF in blood. (2024). European Neuropsychopharmacology, 87, 35–55. https://doi.org/10.1016/j.euroneuro.2024.06.008

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 20.09.2026 | Accepted 21.09.2026 | Online 25.09.2026

12. Silvestri, S., Seeman, M. V., Negrete, J. C., Houle, S., Shammi, C. M., Remington, G. J., et al. (2000). Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology, 152(2), 174–180. https://doi.org/10.1007/s002130000532
13. Silent action of dopamine receptor antagonist in synaptic remodelling: Molecular basis of tardive dyskinesia due to chronic antipsychotic exposure. (2026). Progress in Neuro-Psychopharmacology & Biological Psychiatry, 111846. https://doi.org/10.1016/j.pnpbp.2026.111846
14. Malhi, G. S., & Outhred, T. (2016). Therapeutic mechanisms of lithium in bipolar disorder: Recent advances and current understanding. CNS Drugs, 30(10), 931–949. https://doi.org/10.1007/s40263-016-0380-1
15. Lithium and long-term cognitive outcomes in bipolar disorder and early dementia: A systematic review. (2026). CNS Spectrums. https://doi.org/10.1017/S1092852926100996